Skip to main content
. 2021 Mar 3;137(23):3291–3305. doi: 10.1182/blood.2020009362

Figure 1.

Figure 1.

Univariate analysis of the cumulative incidence of CMV DNAemia comparing HaploCy, SibCy, and SibCNI allogeneic HCT. The incidence of CMV DNAemia was significantly higher among both cohorts receiving PTCy compared with that which did not (P < .0001). Cumulative incidences of CMV DNAemia by day 100 were 40% (99% CI, 35-45), 36% (99% CI, 30-42), and 21% (99% CI, 18-24) for HaploCy, SibCy, and SibCNI, respectively; and by D180 were 42% (99% CI, 37-46), 37% (99% CI, 31-43), and 23% (99% CI, 20-26), respectively. The median times to CMV infection (days) were 38 (range, 2-176), 32 (range, 5-136), and 42 (range, 4-176; P < .001).